Literature DB >> 28525304

Minimal Residual Disease Negativity Is a New End Point of Myeloma Therapy.

Jean-Luc Harousseau1, Herve Avet-Loiseau1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28525304     DOI： 10.1200/JCO.2017.73.1331

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  6 in total

1.  Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials.

Authors:  P Arana; B Paiva; M-T Cedena; N Puig; L Cordon; M-B Vidriales; N C Gutierrez; F Chiodi; L Burgos; L-L Anglada; J Martinez-Lopez; M-T Hernandez; A-I Teruel; M Gironella; M-A Echeveste; L Rosiñol; R Martinez; A Oriol; J De la Rubia; A Orfao; J Blade; J-J Lahuerta; M-V Mateos; J-F San Miguel
Journal:  Leukemia       Date:  2017-11-03       Impact factor: 11.528

Review 2.  Daratumumab for the treatment of AL amyloidosis.

Authors:  M Hasib Sidiqi; Morie A Gertz
Journal:  Leuk Lymphoma       Date:  2018-07-22

Review 3.  Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives.

Authors:  Alessandra Romano; Giuseppe Alberto Palumbo; Nunziatina Laura Parrinello; Concetta Conticello; Marina Martello; Carolina Terragna
Journal:  Front Oncol       Date:  2019-08-20       Impact factor: 6.244

4.  Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis.

Authors:  Giovanni Palladini; Bruno Paiva; Ashutosh Wechalekar; Margherita Massa; Paolo Milani; Marta Lasa; Sriram Ravichandran; Isabel Krsnik; Marco Basset; Leire Burgos; Mario Nuvolone; Ramón Lecumberri; Andrea Foli; Noemi Puig; Melania Antonietta Sesta; Margherita Bozzola; Pasquale Cascino; Alice Nevone; Jessica Ripepi; Pierpaolo Berti; Simona Casarini; Ombretta Annibali; Alberto Orfao; Jesus San-Miguel; Giampaolo Merlini
Journal:  Blood Cancer J       Date:  2021-02-16       Impact factor: 11.037

5.  Tumor Reduction in Multiple Myeloma: New Concepts for New Therapeutics.

Authors:  Rafael Alonso; Juan José Lahuerta
Journal:  Front Oncol       Date:  2022-01-14       Impact factor: 6.244

Review 6.  Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches.

Authors:  Ioannis V Kostopoulos; Ioannis Ntanasis-Stathopoulos; Maria Gavriatopoulou; Ourania E Tsitsilonis; Evangelos Terpos
Journal:  Front Oncol       Date:  2020-05-27       Impact factor: 6.244
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.